First case exceeds 200,000 malignancies survival report: 200,000 cases with 5-year total survival rate of 71%

(Health Times network reporter Wei Wei Fudan University affiliated oncology hospital Wang Guangchao Zhou Changming)
. More than 200,000 cases of cancer, 10 years follow-up data, the total survival rate of patients in 5 years reached 71% ... On April 16th, Fudan University Affiliated Oncology Hospital released a cancer patient survival report showing that from 2008 to 2017 in the hospital diagnosed with malignant tumors and received hospitalization of more than 200,000 cancer patients, after long-term close follow-up, the total survival rate of 3 years and 5 years reached 77.4%, 71%, respectively, the overall survival situation can be comparable to the top cancer centers in Europe and the United States.
", this single center of malignant tumor patient survival report covers breast cancer, pancreatic cancer, prostate cancer, lung cancer and more than a dozen kinds of tumor survival. Professor Guo Xiaomao, director of the oncology hospital, said, "The survival report suggests that whether it is 'red-faced killer' breast cancer, or 'king of cancer' pancreatic cancer, or other malignant tumors, early prevention, early detection and standardized diagnosis and treatment is still the cornerstone of long-term survival of patients, the vast majority of patients with malignant tumors after standardized diagnosis and treatment can get a more ideal prognosis." "
treatment means"combined fist": fill in the anti-cancer "answer"
" as the first case in the country more than 200,000 single center, large-scale, multi-disease long-term follow-up survival report, from which to see, over the past decade, many tumors of the total 5-year survival rate has significantly improved," Professor Guo Xiaomao said, "these survival conditions to a large extent due to standardized treatment concepts and the development of diagnostic technology."
taking the first breast cancer diagnosis data from the cancer hospital as an example, the total survival rate of first breast cancer patients from 2013 to 2017 reached more than 90% in 5 years, significantly higher than the 5-year total survival rate of 88.2% in 2008-2012. In the view of Professor Zhai Zhimin, Director of Breast Surgery and Director of Major Surgery of The Oncology Hospital, the total survival rate of breast cancer patients has improved significantly in 5 years, in addition to the concept of "early prevention and early treatment" is becoming more and more popular, many strategies of the era of molecular classification and precision diagnosis and treatment of breast cancer have brought good results. For example, in the field of breast cancer treatment, due to the development of targeted drugs and endocrine drugs, and obtained a better prognosis, effective classification of three negative breast cancer, so that the "most toxic" breast cancer has the possibility of targeted treatment, chemotherapy drug Gisitabin joint cisplatin treatment, effectively prolonged the life of recurrent metastatic breast cancer ...
. In other types of tumors, the pancreatic surgery team innovated a new method of "nipple residual closed type" pancreatic co-ordination, reducing the rate of pancreatic fistula after pancreatic cancer from 15% to 9.6% of the international average, significantly improving the prognosis of pancreatic cancer patients; Annual survival rate is as high as 63%, of which patients without lymph node metastasis 5 years survival rate is 73%, far higher than the frontier level at home and abroad; prostate cancer surgery methods will be advanced treatment concepts abroad and Chinese anatomical characteristics fusion, to ensure the quality of life of patients, 5 years survival rate of 82.6%; The ultrasound diagnosis of thyroid cancer reached more than 85%, of which the compliance rate of combined cell pathology and molecular pathology diagnosis reached more than 90%, which laid the foundation for precise treatment of thyroid cancer, and the construction of the cavity mirror platform promoted the effective implementation of cavity mirror technology in the chest, gastrointestinal, gynaecological and other tumors, while rooting out the tumor to improve the quality of life of the patients
. Multidisciplinary standardized treatment: "report card" behind the cornerstone
multidisciplinary comprehensive diagnosis and treatment model "tailored" precision, standardized treatment, has become the most standardized model of malignant tumor treatment.
in the treatment of colorectal cancer, 20% of colorectal cancer patients have metastasized at the time of initial consultation, which in the past, once the tumor metastasis means to enter the "late stage" and lose the opportunity to operate. However, with the cooperation of experts from various departments on the multidisciplinary comprehensive diagnosis and treatment platform, patients with colorectal cancer liver metastasis may also get the opportunity of surgery if the lump is moderate in volume and there is no other metastasis outside the liver. According to data released by the Oncology Hospital, the three-year and 5-year survival rates of patients with liver metastasis were 36.11 percent and 21.18 percent, respectively, but the survival rate of patients with liver metastasis after liver excision of bowel cancer was 54.96 percent and 33.87 percent, respectively,
in recent years, the cancer hospital has also "upgraded" the multidisciplinary comprehensive diagnosis and treatment model. Professor Guo Xiaomao introduced that the newly run Oncology Hospital (Pudong Hospital District), the new multidisciplinary comprehensive treatment ward, the solid operation of disease-centered multidisciplinary comprehensive treatment model of tumor. Breaking the previous single-disciplinary "jurisdictional" bed management, in the same disease area to accommodate surgery, internal medicine, radiotherapy and other disciplines, to achieve a multidisciplinary model in the physical space of a high degree of integration. Based on the integrated treatment ward, the hospital will also conduct a number of clinical trials, focusing on cutting-edge research such as refractory oncology treatment programs and innovative drug development.
anti-cancer "pass forward": let malignant tumors become a "chronic disease"
", "has been, early prevention, early diagnosis, early treatment in the tumor prevention is widely popular, so that more early patients get a good survival. The survival data of cancer patients released in this release also significantly reflect the value of the 'three early' concept," Professor Guo Xiaomao said. The proportion of early breast cancer in the initial diagnosis in the tumor hospital has increased significantly in recent years, and the total 5-year survival rate of this part of the patient can reach 97.8%, basically achieve the cure effect, the quality of life of patients is much higher than advanced breast cancer.
, for example, low-dose helical CT screening can detect a 0.5 cm diameter lung cancer lesions, the widespread use of this technology in daily physical examination makes the proportion of early lung cancer patients greatly increased, more early lung cancer can be timely surgery to cure, so as to obtain good results."The survival report also confirms once again that moving the anti-cancer threshold forward can effectively reduce deaths due to disease and error, " said Professor Guo Xiaomao,
. Here, we advocate a healthy lifestyle, early preventive screening, and regular annual cancer prevention check-ups after age 40 are all effective ways for tumors to actively prevent and control and improve early diagnosis rates. We hope that all sectors of the community can participate in science to fight cancer, so that malignant tumors become a preventable and treatable chronic diseases. "
.